Theme · live manifest · live theme JSON
Biotech '24: Established Pharma
5 tickers · $539.74B total market cap
Group: Biotech
As of Spring 2025, the thesis for the Biotech '24: Established Pharma subtheme is mixed. While established pharmaceutical companies like RHHBY, VRTX, REGN, NTRA, and RARE are well-positioned to capitalize on recent advances in biopharmaceutical innovation, they face challenges from regulatory uncertainties and shifts in healthcare policies. The potential for significant breakthroughs in personalized medicine and rare disease treatments remains a key driver of growth, but market volatility and competition from emerging biotech firms could impede consistent performance.
Biotech '24: Established Pharma tracks 5 publicly listed stocks in this theme: NTRA, RARE, REGN, RHHBY, VRTX. See the constituent table for details.
Thesis update: 2025-04-01
Constituents
Build 20260520T081747
| Company | Previous Quarter Report Date | Next Expected Report Date | Last Quarter Earnings Move % | Earnings Move % | Intra-Quarter Move % | Since Last Report % | Market cap | Weight |
|---|---|---|---|---|---|---|---|---|
Roche Holding AGRHHBY | 01/29/2026 (BMO) | — | -0.47% | — | -8.62% | — | $334.02B | 20.0000 |
Vertex Pharmaceuticals IncorporatedVRTX | 05/04/2026 (AMC) | 05/04/2026 (AMC) | 5.69% | 0.10% | -12.54% | 2.34% | $110.23B | 20.0000 |
Regeneron Pharmaceuticals, Inc.REGN | 04/29/2026 (BMO) | 04/29/2026 (BMO) | -1.07% | -3.38% | -1.31% | -10.86% | $65.49B | 20.0000 |
Natera, Inc.NTRA | 05/07/2026 (AMC) | 05/07/2026 (AMC) | -3.73% | -9.69% | 5.66% | 0.93% | $27.78B | 20.0000 |
Ultragenyx Pharmaceutical Inc.RARE | 05/05/2026 (AMC) | 05/05/2026 (AMC) | -12.68% | 4.51% | 21.88% | -13.42% | $2.21B | 20.0000 |
| Average | -2.45% | -2.11% | 1.02% | -5.25% | $107.95B | 20.0000 | ||
| Median | -1.07% | -1.64% | -1.31% | -4.96% | $65.49B | 20.0000 | ||
| Std Dev | 5.97% | 5.19% | 12.16% | 6.96% | $118.76B | 0.0% | ||
| Min | -12.68% | -9.69% | -12.54% | -13.42% | $2.21B | 20.0000 | ||
| Max | 5.69% | 4.51% | 21.88% | 2.34% | $334.02B | 20.0000 | ||
| % Positive Tickers | 20.00% | 50.00% | 40.00% | 50.00% |
* Provisional value: before LstRpt% reaches its 2-day post-report lock window (BMO/AMC adjusted), EarningsPerf is calculated from current vs pre-report and then locks to final LstRpt%.